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cutaneous Crohn’s Disease
Shantini A Rice1†, Pick N Woo1†, Emad El-Omar2, Ronald A Keenan3 and Anthony D Ormerod2*Abstract
Background: Cutaneous Crohn’s Disease is a notoriously difficult condition to treat and causes significant
morbidity, impacting heavily on quality of life. This is the first study in adults examining the effect of topical
tacrolimus on the different cutaneous manifestations of Crohn’s Disease.
Methods: This open label observational study of 20 patients with heterogeneous forms of cutaneous Crohn’s
disease used topical tacrolimus 0.1% ointment once daily to affected areas for 12 weeks with a maximal total dose
of 90g. Therapy was stopped at 12 weeks to assess whether the condition relapsed. Thereafter relapsing patients
optionally continued an open label extension of topical tacrolimus therapy and were observed for a total of 12
months.
Results: Of seventeen patients completing the twelve-week study, fifteen improved using a specifically designed
physicians’ global severity scale. One patient cleared, four showed a pronounced improvement (51-75%) and ten
demonstrated a mild (1-25%) or moderate improvement (25-50%) in twelve weeks. Over twelve months eleven
patients remained in the study, nine of which improved, one cleared and one showed no change. Perineal disease
responded better with two out of twelve clearing, four showing pronounced benefit and four mild to moderate
improvement. Long-term application of 0.1% tacrolimus applied to broken skin and mucosa was safe and serum
levels of tacrolimus were undetectable in all subjects throughout the study.
Conclusion: 0.1% tacrolimus ointment was safe and effective in treating cutaneous manifestations of Crohn’s
disease, particularly perineal disease and pyoderma gangrenosum, yet it seldom cleared the condition.
Clinical trial registration: ClinicalTrials.gov Protocol Registration System ID: 33000332Background
Crohn’s disease is a chronic inflammatory bowel disease
of unknown aetiology with distinctive mucocutaneous
manifestations. Cutaneous Crohn’s Disease (Cutaneous
CD) is relatively common with an incidence between
11% and 44% of individuals with Crohn’s disease of the
bowel being affected. The Grampian region in Scotland
appears to have the highest incidence of cutaneous
Crohn’s in Europe [1-5]. It causes significant morbidity
and severely impacts upon quality of life [6,7].
There are three distinct manifestations of cutaneous
Crohn’s [8-10]. The most common types are perianal dis-
ease (PD), often with fissuring or fistulae, granulomatous* Correspondence: a.d.ormerod@abdn.ac.uk
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reproduction in any medium, provided the orcheilitis and peristomal pyoderma gangrenosum (PPG).
The latter is often related to the severity of the gastro-
intestinal disease and has been treated with topical
tacrolimus [11].
The second category encompasses conditions that
have persistently been reported as having a strong asso-
ciation with Crohn’s disease, such as classical pyoderma
gangrenosum, erythema nodosum, erythema multiforme,
acrodermatitis enteropathica and epidermolysis bullosa
acquisita.
The last and most uncommon type is that of granu-
lomatous cutaneous lesions which are non-contiguous
with the gastro-intestinal tract. This is often referred to
as metastatic Crohn’s Disease (MCD) and has a predilec-
tion for skin folds but may also involve other sites such
as the face, vulva, penis, trunk and limbs [12].
Severe perineal disease, PPG and MCD are notoriously
difficult to treat and are frequently resistant to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Physicians global severity scale
6 Worse
5 No change
4 Mild improvement: 1-25%
3 Moderate improvement: 26-50%
2 Pronounced improvement: 51-75%
1 Almost clear: 76 to <100% improvement
0 Completely clear: 100% improvement
Figure 1 Patient flowchart.
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and immunomodulating agents such as azathioprine,
ciclosporin and sulphasalazine. Activation of Th1 lym-
phocytes plays a crucial role in the mucosal destruction
and this can be inhibited by the calcineurin inhibitors
ciclosporin A and tacrolimus [13]. As tacrolimus is 10–
100 times more potent than ciclosporin [14] and better
able to penetrate skin well due to its lower molecular
weight we hypothesise that tacrolimus 0.1% ointment
will be an effective and safe treatment in the manage-
ment of cutaneous Crohn’s Disease.
Tacrolimus has become an important addition to ther-
apy for atopic dermatitis [15] and other inflammatory
dermatoses including psoriasis, allergic contact dermatitis,
graft-versus-host disease and recalcitrant leg ulcers with
rheumatoid arthritis, all with beneficial outcome [16-21].
Of particular note, it has been reported to be effective
in erosive oral lichen planus [22,23] and in otherwise
treatment-resistant pyoderma gangrenosum [11].
There are few studies that evaluate the benefit of topical
tacrolimus on cutaneous Crohn’s. A series of subjects with
oral and perianal Crohn’s disease reported efficacy with
marked improvement in 7 out of 8 children of 0.05%
tacrolimus made up from the intravenous formulation
[24]. A more recent study randomised 19 patients to 0.1%
topical tacrolimus with 3 of 4 patients healing ulcerating
disease but poor responses for fistulae [25]. There are
case reports of improvement of parastomal pyoderma
gangrenosum [11] with topical therapy. Increasingly
tacrolimus has been shown to be useful as a systemic
agent in Crohn’s disease [26-29] and in treating resistant
disease [27,30] particularly showing efficacy for fistulating
disease [31,32].
This study is the first to look at the effect of topical
tacrolimus 0.1% on the different cutaneous manifestations
of Crohn’s in adults. We found it to be effective in redu-
cing the severity of several of the cutaneous manifestations
of Crohn’s disease particularly pyoderma gangrenosum
and perianal disease. However the disease was seldom
cleared, improvement was slow and rapid relapses were
seen where treatment was not maintained. Concerns of
possible systemic absorption of tacrolimus [33] when
applied to broken skin and mucosal surfaces were
addressed in this study.Methods
This was an open label study of 20 patients with cutaneous
Crohn’s Disease using topical tacrolimus 0.1% ointment
once daily to affected areas for 12 weeks with a maximal
total dose of 90g. Therapy was stopped at 12 weeks to
assess whether the condition relapsed. Thereafter relapsing
patients optionally continued an open label extension of
topical tacrolimus 0.1% and were observed for a total of 12
months. The study was conducted at the Dermatology De-
partment of Aberdeen Royal Infirmary. The protocol was
approved by North of Scotland Research Ethics Committee
and all patients provided written informed consent to par-
ticipation and to publication of photography and clinical
databefore inclusion in the study.
Figure 2 Patient 19 with perineal disease. Figure 4 Patient 13 with perineal disease.
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leaflets to consultant gastroenterologists and surgeons in
Aberdeen Royal Infirmary between October 2002 and
December 2003. Patients suitable for the study were
offered an appointment within two weeks of contacting
the department.
Patients aged twelve years or more with a willingness
and capability to follow the study procedure were
considered for inclusion. Each subject had to have a
confirmed diagnosis of Crohn’s disease of at least three
months’ duration confirmed by radiography, endoscopy
or pathological examination and were required to have a
skin manifestation of Crohn’s disease. Both male and
female subjects with reproductive potential required to
be on an acceptable form of birth control for the
duration of the study. Long-standing, concomitant
immunosuppressive therapy was allowed if the dose was
stable and not controlling the skin problem.Figure 3 Patient 19 with perineal disease: cleared with course
of treatment.Patients were excluded if they had had a known sensi-
tivity to tacrolimus, a change in aminosalicylate dosage
in the four weeks prior to screening, were on oral ster-
oids at over 40 mg per day, had been commenced on
methotrexate, azathioprine or ciclosporin within the last
two months or an anti- TNF monoclonal antibody within
the three months prior to screening. Patients having had a
stoma fashioned less than three months before enrolment,
those with an immunocompromising disease, a diagnosis of
malignancy within the last five years, any other condition,
past or present treatment thought by the investigator to
render the subject ineligible for the study were excluded, as
were those with erythema nodosum.
Subjects were instructed to apply topical tacrolimus
0.1% ointment to their skin lesions once daily for three
months. Therapy was then stopped for a month and if
relapse occurred subjects could recommence therapy for
up to 1 year.Figure 5 Patient 13 with perineal disease: moderate
improvement with treatment.
Figure 6 Patient 18 with granulomatous cheilitis.
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standardised digital photography by three independent
assessors. As no validated measures were available the
investigators specifically designed a Physicians’ Global
Severity Scale to assess global cutaneous disease severity
when patients had received at least 12 weeks’ treatment.
The Scale was used to assess improvement by examin-
ation of photographs taken before and during treatment
(Table 1).
Other methods used for assessment over 52 weeks
included a global self-assessment score and the vali-
dated Perineal Disease Activity Index (PDAI), where
appropriate for perineal disease. A potential confounder
in this study was a deterioration of cutaneous signs
secondary to a systemic worsening of Crohn’s disease.
The Crohn’s Disease Activity Index (CDAI) was used to
control for this.
The PDAI incorporates five elements: the presence or
absence of discharge, pain or restriction of daily living,Figure 7 Patient 18 with granulomatous cheilitis: moderate
improvement of lip swelling with treatment.restriction of sexual activity, the type of perianal disease,
the degree of induration, yielding a composite score ran-
ging from 0 to 20 with higher scores indicating more se-
vere disease. The CDAI is a validated test which
incorporates eight related variables: the number of liquid
or very soft stools per day, the severity of abdominal pain
or cramping, general well-being, the presence or absence
of an abdominal mass, the use or non-use of anti-
diarrhoeal drugs, the haematocrit and body weight. The
scores range from 0 to 600 with scores below 150 indicat-
ing remission and those above 450 indicating severe
illness.
Safety evaluations included recording of side effects,
physical examination including tracing and photographs,
and vital signs measured by a single investigator during
the study. As the tacrolimus was being applied to areas
lacking a skin barrier, fistulae, ulcerated and mucosal
surfaces, systemic tacrolimus levels were measured at
every visit to assess any significant systemic absorption.
Blood pressure, urinalysis and renal function were
measured and remained constant throughout the study.Results and discussion
Twenty patients aged between 12 and 66 years with 12
males and 8 females were enrolled in the trial. Nine
patients had perianal disease; five granulomatous cheilitis;
one metastatic Crohn’s disease; two pyoderma gangre-
nosum, one in the peristomal region. The 3 remaining
patients had perianal disease plus either PG or MCD.
Out of the twenty patients, seventeen completed 12
weeks of treatment. The primary outcome measured
using the physicians’ global severity scale from clinical
photographs demonstrated a median improvement of
“moderate improvement” (4 on the 6 point scale)
equivalent to 26-50% improvement in the seventeen
patients. The three independent assessors showed a fair
intra-observer agreement with weighted Kappa-scores of
0.31, 0.38 and 0.38 (0.2-0.4 = fair agreement) (Figure 1).
At 12 weeks, the greatest improvement with treatment
was noted in patients with PD. Disease clearance was
noted for one patient (Figures 2 and 3). Another patient
whose PD cleared rapidly left the trial early no longer
requiring treatment. Pronounced improvement was
evident in four patients, two with PD and two with PD
and MCD, (although with a moderate response of the
MCD to treatment in one). Four patients had a mild or
moderate improvement (see Figures 4 and 5). A patient
with perianal disease and sinus formation did not
improve at this point.
There were three patients with PG and two had mild
or moderate improvement; the other withdrew at 4
weeks due to intolerable side effects but had improved
up to this point.
Table 2 Patient demographics and overall response to treatment
AGE
years
SEX CONDITION DURATION
years*
CONCOMITANT
THERAPIES
OVERALL RESPONSE TO
TREATMENT ^
NOTES
1 35 F PD 1.5 Azathioprine 1yr,
prednisolone
Cleared Relapsed on stopping at 12
weeks
2 27 M PD, MCD 4 Azathioprine 1yr,
Prednisolone, Asacol
Two areas healed rest improved
prior to exiting
Dropped out due to flare of
Crohn’s
3 60 F PG 33 Azathioprine 2yr, Predfoam,
Asacol
Improved Dropped out - intolerable pain
from ointment
4 65 F PD 10 Nil Improved Relapsed on stopping at 12
weeks
5 33 M GC 12 Nil Improved initially, worsened
during extension
Relapsed on stopping at 12
weeks
6 37 F GC 5 Prednisolone Improved Less frequent and severe
swelling.
7 20 M PD 3 Azathioprine 5yr,
Methotrexate
Improved Dropped out - severe flare of
systemic disease
8 12 M GC 5 Nil Moderate improvement Relapsed on stopping at 12
weeks
9 32 M MCD 4 Azathioprine 2yr No change
10 66 M PD 1.5 Nil Initial improvement Relapsed on stopping at 12
weeks
11 42 M PD 17 Nil Improved
12 16 M GC 13 Nil Mild improvement Relapsed on stopping at 12
weeks
13 56 F PD 15 Asacol, Predfoam Moderate improvement Relapsed on stopping at 12
weeks
14 29 F PD 1.5 Nil No change
15 35 M PD 0.75 Nil Pronounced improvement Relapsed on stopping at 12
weeks
16 63 F PG, PD 6 Nil Pronounced improvement Systemic disease flared week 9
17 33 M PD 5 Nil Skin healed at 8 weeks but pain
continued
Exited trial at week 8
18 15 M GC 10 Nil Moderate improvement of lip
swelling
Fewer mouth ulcers, relapsed
19 30 M PD, MCD 25 Nil Cleared
20 38 F PPG 1.5 Prednisolone,
methotrexate, infliximab
Pronounced improvement Relapsed on stopping at 12
weeks
* Duration of diagnosis of cutaneous Crohn’s disease; ^ Physicians Global Assessment; PD perineal disease; GC granulomatous chelitis; MCD mixed connective
tissue disease; PPG peristomal pyoderma gangrenosum.
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improved but only to a mild or moderate extent (Figures 6
and 7) and four relapsed after stopping therapy. The
patient with MCD did not experience any improvement in
disease at 12 weeks.
Ten patients relapsed within 3–9 days of cessation of
treatment. Eleven patients chose to continue the study
for a further 36 weeks. One of these patients (with PD)
had disease clearance as measured by the Physicians’
Global Severity Scale, 9 had an overall improvement in
their cutaneous Crohn’s disease (6 with PD, 1 with GC,
2 with PG) and 1 showed no change (PD). Interestingly,
the two patients with PG had shown only a mild or
moderate improvement at week 16, but had pronounced
improvements by the end of the 52 weeks (Table 2).As perineal disease was the most frequent cutaneous
manifestation, a subgroup analysis of patients with PD
was conducted. Three of these patients did not complete
12 weeks of treatment; one dropped out due to a sys-
temic flare at 9 weeks but had pronounced improvement
in perineal disease at the point of exit and another
patient exited early when the perineal disease cleared.
The remaining patient with exiting early had a flare in
systemic Crohn’s. Of those completing 12 weeks of treat-
ment, disease clearance was noted for one patient,
pronounced improvement in three and a further four
had a mild or moderate improvement (Figure 8).
However, at week 12 when treatment was stopped, six
of these improvers relapsed and elected to join the trial
extension. With continued treatment beyond the initial
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Figure 8 Patients with Perineal Disease who completed 12 weeks of treatment showing change in Perineal Disease Activity Index
during this period. Note Patient 2 had a flare of Crohn’s unrelated to treatment; Patient 10 flared after stopping treatment.
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patient achieved clearance of PD. Only one patient could
maintain clinical improvement with cessation of treat-
ment at week 12 (Figure 9).
Eight patients reported burning, itching or discomfort
with topical application of tacrolimus. Four patients
described this side effect as a brief symptom immediately
after application; another dropped out as a result of it.
Conversely, five patients commented on improvement of
local discomfort with continued use of topical tacrolimus.
Systemic absorption of tacrolimus was undetectable in all
patients throughout the study with blood levels of tacro-
limus at every visit being below the limits of detection
despite daily application to mucosal surfaces and broken
or ulcerated skin in all cases.Conclusion
There is limited evidence for the efficacy of the commer-
cial preparation of 0.1% tacrolimus (ProtopicW, Fujisawa)
in the treatment of perineal Crohn’s disease and pyoderma
gangrenosum. We found it to be effective in reducing the
severity of several of the cutaneous manifestations of
Crohn’s disease.
However, our study found that it seldom cleared
cutaneous Crohn’s disease. Improvement was slow
and rapid relapses were seen when treatment was
not maintained; ten patients relapsed within 3 to 9
days of stopping treatment at week 12 and thustreatment was extended to 12 months. The problem
of relapse after abrupt cessation of treatment was
noted to occur in two of the patients in the study
conducted by Casson et al [24].
The most favourable results were seen in our patients
with perianal disease and pyoderma gangrenosum with
reduction of inflammation and promotion of ulcer heal-
ing. In the case of PD, treatment needed to be continued
in most cases in order to maintain the response. PG,
was slower to respond and seemed to reach a peak
improvement well beyond 12 weeks where treatment
was continued. Indeed topical tacrolimus at lower con-
centrations has previously been shown to be useful
in the management of perineal Crohn’s disease and
peristomal pyoderma gangrenosum in children [24].
However, we found that fistulae and sinuses tended not
heal, in keeping with the findings of Hart et al [25].
Patients with granulomatous cheilitis showed mild
improvement with reduced severity and frequency of
flares. Associated aphthous ulceration in our patients
also improved, a tendency noted by Casson et al. who
found improvement in 3 children with oral disease [24].
The efficacy of topical immunosuppressive agents can
be limited by the size of the molecule in relation to the
skin barrier. However, the predominantly ulcerative
lesions of cutaneous Crohn’s disease are without an epi-
dermal barrier and thus more permeable, maximising
the therapeutic potential of a topical drug. Conversely,
skin absorption is impeded in fistulae by their anatomy
N = 12
Patients with 
perineal 
disease
N = 3
Dropped out
N = 1
Cleared early
N = 2 
Flare of 
systemic  
Crohn's
N = 9
Completed  
12 weeks of 
treatment
N = 1
No change
N = 4
Mild to 
moderate 
improvement
N = 3
Relapsed  
then returned  
to treatment
N = 1
Dropped out
N = 3
Pronounced 
improvement
N = 2
Relapsed  
then returned  
to treatment
N = 1
Flare of 
systemic 
disease
N = 1
Improvement 
sustained
N = 1
Cleared
Relapsed  
then returned  
to treatment
Cleared
Figure 9 Flowchart of patients in study with Perineal Disease
showing responses to initial 12-week treatment course then
open-label extension.
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ever, effective for fistulae [31].
Future work in this field should investigate the efficacy
of a long-term maintenance regime of topical tacrolimus
in preventing relapses of cutaneous Crohn’s, similar to
that used in the treatment of atopic eczema.
Limitations of this study
Our study was necessarily limited by the small number
of participants meeting the inclusion criteria who wished
to participate. We acknowledge that the separate cutane-
ous features of Crohn’s disease are heterogeneous but in
the context that they present clinically and with very
limited published evidence, such an observational pro-
spective study of a new therapy adds to our knowledge
of treatment. We also had to develop our non validated
rating scale to accommodate the heterogeneous mani-
festations although supplementing validated scores in-
cluding PDAI for relevant cases. Although erythema
nodosum (EN) is the commonest cutaneous manifest-
ation of Crohn’s disease, it was not included in this
study. As the pathology found in EN is within thesubcutaneous fat with an intact overlying epidermis, it
is unlikely that topical tacrolimus could penetrate to or
be effective at this level of the skin. Additionally, EN
tends to be self-limiting.
The primary outcome measure was dependant on the
quality of both the photographers’ skill and the prints
and the Kappa score reflected only fair agreement
between the assessors. Patients with enteral Crohn’s
disease are often on some long-term preventive steroid
or immunomodulatory therapy to control their enteral
disease. Seven of our patients were taking low dose
prednisolone or azathioprine, but these long term main-
tenance therapies were ongoing for at least a year at
doses stable for the preceding three months, and were
not sufficient to control the cutaneous disease. Where a
flare in systemic disease led to new immunosuppressives
being prescribed or high dose steroids patients were
discontinued from the study. As this was an open label
trial without a control arm, we cannot report on the
natural history of untreated lesions of cutaneous Crohn’s
disease although placebo treatment in the study by Hart
[25] did not lead to improvement despite concomitant
systemic immunosuppressive therapies.
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